These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35290421)

  • 21. Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.
    Mansoor LE; Yende-Zuma N; Baxter C; Mngadi KT; Dawood H; Gengiah TN; Samsunder N; Schwartz JL; Doncel GF; Abdool Karim Q
    J Int AIDS Soc; 2019 Sep; 22(9):e25381. PubMed ID: 31507088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased condom use among key populations using oral PrEP in Kenya: results from large scale programmatic surveillance.
    Manguro GO; Musau AM; Were DK; Tengah S; Wakhutu B; Reed J; Plotkin M; Luchters S; Gichangi P; Temmerman M
    BMC Public Health; 2022 Feb; 22(1):304. PubMed ID: 35164707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
    Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Donnell D; Baeten JM;
    J Int AIDS Soc; 2020 May; 23(5):e25491. PubMed ID: 32396700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
    Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
    AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "It went through the roof": an observation study exploring the rise in PrEP uptake among Zimbabwean female sex workers in response to adaptations during Covid-19.
    Matambanadzo P; Busza J; Mafaune H; Chinyanganya L; Machingura F; Ncube G; Steen R; Phillips A; Cowan FM
    J Int AIDS Soc; 2021 Oct; 24 Suppl 6(Suppl 6):e25813. PubMed ID: 34713613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using a HIV prevention cascade for identifying missed opportunities in PrEP delivery in Kenya: results from a programmatic surveillance study.
    Were D; Musau A; Mutegi J; Ongwen P; Manguro G; Kamau M; Marwa T; Gwaro H; Mukui I; Plotkin M; Reed J
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25537. PubMed ID: 32602658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial.
    Irungu EM; Mugwanya KK; Mugo NR; Bukusi EA; Donnell D; Odoyo J; Wamoni E; Peacock S; Morton JF; Ngure K; Mugambi M; Mukui I; O'Malley G; Baeten JM;
    Lancet Glob Health; 2021 Dec; 9(12):e1730-e1739. PubMed ID: 34798031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.
    Van Epps P; Wilson BM; Garner W; Beste LA; Maier MM; Ohl ME
    J Acquir Immune Defic Syndr; 2019 Dec; 82(5):427-430. PubMed ID: 31714421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT.
    Velloza J; Heffron R; Amico KR; Rowhani-Rahbar A; Hughes JP; Li M; Dye BJ; Celum C; Bekker LG; Grant RM;
    AIDS Behav; 2020 Jul; 24(7):2178-2187. PubMed ID: 31955360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.
    Beesham I; Joseph Davey DL; Beksinska M; Bosman S; Smit J; Mansoor LE
    AIDS Behav; 2022 Aug; 26(8):2623-2631. PubMed ID: 35122575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PrEP rollout in Africa: status and opportunity.
    Irungu EM; Baeten JM
    Nat Med; 2020 May; 26(5):655-664. PubMed ID: 32405065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial.
    Haberer JE; Bukusi EA; Mugo NR; Pyra M; Kiptinness C; Oware K; Garrison LE; Thomas KK; Musinguzi N; Morrison S; Anderson PL; Ngure K; Baeten JM;
    Lancet HIV; 2021 Mar; 8(3):e130-e137. PubMed ID: 33662265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
    Liu AY; Cohen SE; Vittinghoff E; Anderson PL; Doblecki-Lewis S; Bacon O; Chege W; Postle BS; Matheson T; Amico KR; Liegler T; Rawlings MK; Trainor N; Blue RW; Estrada Y; Coleman ME; Cardenas G; Feaster DJ; Grant R; Philip SS; Elion R; Buchbinder S; Kolber MA
    JAMA Intern Med; 2016 Jan; 176(1):75-84. PubMed ID: 26571482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model.
    Maloney KM; Le Guillou A; Driggers RA; Sarkar S; Anderson EJ; Malik AA; Jenness SM
    J Infect Dis; 2021 Jan; 223(1):72-82. PubMed ID: 32882043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delivering PrEP to Young Women in a Low-Income Setting in South Africa: Lessons for Providing Both Convenience and Support.
    Cassidy T; Ntuli N; Kilani C; Malabi N; Rorwana B; Mutseyekwa T; O'Connell R; Steele SJ; Ndlovu Z; Ellman T; de Azevedo V; Pfaff C; Nelson A; Duran LT
    AIDS Behav; 2022 Jan; 26(1):147-159. PubMed ID: 34259963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa.
    Little KM; Flomen L; Hanif H; Anderson SM; Thurman AR; Clark MR; Doncel GF
    AIDS Behav; 2022 Sep; 26(9):3099-3109. PubMed ID: 35360893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "The Drug Will Help Protect My Tomorrow": Perceptions of Integrating PrEP into HIV Prevention Behaviors Among Female Sex Workers in Lilongwe, Malawi.
    Shea J; Bula A; Dunda W; Hosseinipour MC; Golin CE; Hoffman IF; Miller WC; Go VF; Lungu T; Lancaster KE
    AIDS Educ Prev; 2019 Oct; 31(5):421-432. PubMed ID: 31550194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women.
    Celum CL; Delany-Moretlwe S; McConnell M; van Rooyen H; Bekker LG; Kurth A; Bukusi E; Desmond C; Morton J; Baeten JM
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20227. PubMed ID: 26198350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.